Endpoints NewsUpdated: Takeda bets $400M cash on colorectal cancer drug in boost to China's HutchmedJan 23, 2023more_vert
Business WireTakeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED's Fruquintinib, a Highly Selective, Oral ...Jan 23, 2023more_vert